EBOVAC1 consortium reports that Investigational Ebola Vaccine Regimen Induced Durable Immune Response 1 Year After Vaccination - 14th March 2017
Based on final Phase 1 data published in JAMA: The Journal of the American Medical Association, the prime-boost Ebola vaccine regimen induced an antibody response that persisted in 100 percent of healthy volunteers to at least 1 year following vaccination. The results are from the EBOVAC1 study EBL1001 conducted by the Oxford Vaccine Group in the UK.
EBOVAC2 report on BBC News - 8th March 2017
Victoria Derbyshire reporter Catrin Nye went to visit the Oxford Vaccine Group looking for volunteers who participated in the EBL2001 study. Prof. Andrew Pollard (Professor of Paediatric Infection and Immunity and Oxford Vaccine Group PI for EBOVAC1 and EBOVAC2 ) and study volunteers were interviewed.
Watch here : http://www.bbc.co.uk/news/uk-39202974
